Abstract Library

#4665 Prognostic value of systemic inflammatory parameters in neuroendocrine tumour patients treated with peptide receptor radionuclide therapy – Preliminary results

Introduction: PRRT (177Lu-Dotatate) is a therapeutic option for advanced NETs (neuroendocrine tumours). Systemic inflammatory parameters, such as NLR, PLR, SII, and other ratios derived from complete blood counts, are considered prognostic markers in NETs and other malignancies.

Conference:

Presenting Author: Maciejewski A

Authors: Maciejewski A, Komarnicki P, Musiałkiewicz J, Gut P, Ruchała M,

Keywords: neuroendocrine tumour, PRRT, systemic inflammatory parameter, PLR, prognostic biomarker,

#4657 Should we use the growth modulation index (GMI) in response assessment in G2 neuroendocrine tumours (NETs)?

Introduction: Grade 2 (G2) neuroendocrine tumours (NETs) exhibit diverse behaviours ranging from indolent to aggressive malignancies. Growth Modulation Index (GMI) is the ratio between time to progression (TTP) with a line of therapy (TTPn) and that of the previous line of therapy (TTPn-1). A GMI value equal to or greater than 1,33 has been suggested as an indicator of clinical effectiveness beyond traditional metrics.

Conference:

Presenting Author: Bertuzzi A

Authors: Bertuzzi A, Ferrillo G, Laffi A, Evangelista L, Jandric J,

Keywords: growth modulation index (GMI), G2 gastroenteropancreatic neuroendocrine tumour (GEP-NET), tumour response assessment,

#4655 A novel nonpeptide drug conjugate (NDC) for the treatment of somatostatin receptor 2-expressing tumours

Introduction: Somatostatin receptor 2 (SST2) is an established target for the treatment of NETs and potentially other solid tumours.

Conference:

Presenting Author:

Authors: Zhao J, Sturchler E, Yang B, Chen M, Tang Y,

Keywords: somatostatin, solid tumour, drug conjugate, internalisation, cytotoxicity,

#4651 Neuroendocrine hyperplasia of infancy (NEHI) vs. diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): What is the difference?

Introduction: Neuroendocrine Hyperplasia of Infancy (NEHI) is a rare disease that belongs to the group of interstitial lung disease in children; characterised by hypoxemia, tachypnoea, and respiratory distress, often misdiagnosed as reactive airway disease or bronchiolitis. The diagnosis relies on histologic evaluation. We describe the clinical presentation and paraclinical characteristics of paediatric patients with NEHI.

Conference:

Presenting Author:

Authors: González Devia D, Restrepo Gualteros S, Ortiz Pérez M, Fernández Hernández B,

Keywords: Neuroendocrine Hyperplasia of Infancy, Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, child,

#4647 Crosstalk between cancer-associated fibroblasts and small intestinal neuroendocrine tumour cells in a 3D spheroid model

Introduction: At diagnosis, over 50% of small intestinal neuroendocrine tumours (SI-NETs) have metastasised to the mesentery where they often induce extensive fibrosis. Recent studies highlight the crucial interaction between SI-NET cells and cancer-associated fibroblasts (CAFs) in the pathogenesis of mesenteric fibrosis (MF).

Conference:

Presenting Author:

Authors: van der Slik E, Feelders R, van Koetsveld P, Iyer A, Hofland J,

Keywords: mesenteric fibrosis, small intestinal neuroendocrine tumour, CAF,